A. Menarini Asia-Pacific has signed a licensing agreement with Mitsubishi Tanabe Pharma to commercialize and promote avanafil in China, Hong Kong, Macao, Taiwan, Indonesia, Malaysia, Philippines, Singapore, Thailand and Vietnam. Menarini Group has already been licensed to market the product in over 40 European countries, plus Australia and New Zealand.
Avanafil is a phosphodiesterase – 5 inhibitor (PDE5-i) approved In Europe and in the United States for the treatment of erectile dysfunction.